Evolutionary Genomics (Evolutionary Genomics) Cash And Cash Equivalents : $0.58 Mil (As of Dec. 2022)

View and export this data going back to 2011. Start your Free Trial

What is Evolutionary Genomics Cash And Cash Equivalents?

Evolutionary Genomics's quarterly cash and cash equivalents declined from Jun. 2022 ($0.90 Mil) to Sep. 2022 ($0.77 Mil) but then stayed the same from Sep. 2022 ($0.77 Mil) to Dec. 2022 ($0.58 Mil).

Evolutionary Genomics's annual cash and cash equivalents declined from Dec. 2020 ($0.22 Mil) to Dec. 2021 ($0.21 Mil) but then increased from Dec. 2021 ($0.21 Mil) to Dec. 2022 ($0.58 Mil).

Evolutionary Genomics Cash And Cash Equivalents Historical Data

The historical data trend for Evolutionary Genomics's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evolutionary Genomics Cash And Cash Equivalents Chart

Evolutionary Genomics Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Cash And Cash Equivalents

Get a 7-Day Free Trial

0.13

0.05

0.22

0.21

0.58

Evolutionary Genomics Quarterly Data
	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22
Cash And Cash Equivalents	Get a 7-Day Free Trial															0.21	1.04	0.90	0.77	0.58

Evolutionary Genomics Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Evolutionary Genomics (OTCPK:FNAM) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Evolutionary Genomics Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Evolutionary Genomics's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Evolutionary Genomics (Evolutionary Genomics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Evolutionary Genomics Inc (OTCPK:FNAM) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

N/A

Address

4220 Morning Star Drive, Castle Rock, CO, USA, 80108

Website

https://www.evolgen.com

Evolutionary Genomics Inc is involved in the development of a technology platform, the Adapted Traits Platform (ATP), to identify commercially valuable genes that control important traits in animals and plants. It uses the ATP to identify genes to improve crop plant traits such as yield, sugar content, biomass, drought tolerance, and pest/disease resistance. The company's platform identifies key genes that have changed successfully to impart new or improved traits. Its primary source of revenue had been contract services revenue for research performed by it on behalf of other commercial entities and grant income received from governmental agencies, industry associations and grant-making foundations for research performed.

Executives

Steve B Warnecke	director, 10 percent owner, officer: Chairman, CEO	C/O TARGETED MEDICAL PHARMA, INC., 2980 BEVERLY GLEN CIRCLE, SUITE 301, LOS ANGELES CA 90077
Virginia P. Orndorff	director	4580 AUGUSTA DR., BROOMFIELD CO 80023
Walter Messier	officer: Secretary / Treasurer	1586 GOSHAWK DRIVE, LONGMONT CO 80504
Mark Virgil Boggess	director	7857 E OAKBROOK CIR, MADISON WI 53717
Sanford Schwartz	director, 10 percent owner	5353 MANHATTAN CIRCLE, STE 101, BOULDER CO 80303
Michael Friess	director, 10 percent owner, officer: President/CEO	5353 MANHATTAN CIRCLE, STE 101, BOULDER CO 80303
Chloe M Divita	director, officer: Secretary/Treasurer/CFO	5353 MANHATTAN CIRCLE, SUITE 101, BOULDER CO 80303

Evolutionary Genomics (Evolutionary Genomics) Headlines

No Headlines